Document Detail


Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers.
MedLine Citation:
PMID:  23408309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Neurodegenerative diseases such as Huntington disease, Parkinson's disease, and Alzheimer's disease are caused by the accumulation of aggregate prone proteins. Pathogenic proteins misfold, aggregate, and escape the cell's normal degradative pathways. Protein aggregates subsequently lead to the toxic disruption of normal cellular processes leading, ultimately, to disease. Several lines of evidence suggest that reducing the burden of these toxic aggregates is therapeutic. One mechanism proposed to facilitate the degradation or clearance of these protein inclusions is macroautophagy. While autophagic treatment paradigms for neurodegeneration are still in the early stages of preclinical development, it is essential to identify and validate methods to measure the activation of autophagy in human patients. These methods will serve as important biomarkers necessary to test compound efficacy and monitor clinical improvement.
Authors:
Conrad C Weihl
Related Documents :
24052039 - Differential diagnosis of glomerular disease: a systematic and inclusive approach.
24918119 - Omics profiles in chronic venous ulcer wound fluid: innovative applications for transla...
24991229 - Public health for the people: participatory infectious disease surveillance in the digi...
21285059 - Polymyositis associated with severe interstitial lung disease: remission after three do...
24470989 - Autophagy modulation in disease therapy: where do we stand?
23642059 - Differences between parkinson's and huntington's diseases and their role for prioritiza...
7498669 - Diagnosis of wilson's disease in an asymptomatic sibling by dna linkage analysis.
10949879 - Some memoranda on the diagnostic criteria of lung disease caused by mycobacterium avium...
17938929 - Telomerase activity in connective tissue diseases: elevated in rheumatoid arthritis, bu...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics     Volume:  10     ISSN:  1878-7479     ISO Abbreviation:  Neurotherapeutics     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-07-05     Completed Date:  2014-02-10     Revised Date:  2014-07-01    
Medline Journal Info:
Nlm Unique ID:  101290381     Medline TA:  Neurotherapeutics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  383-90     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autophagy / physiology*
Biological Markers / metabolism
Humans
Nerve Tissue Proteins / metabolism*
Neurodegenerative Diseases / metabolism*,  therapy*
Protein Folding*
Grant Support
ID/Acronym/Agency:
K02 AG042095/AG/NIA NIH HHS; K02AG042095/AG/NIA NIH HHS; R01 AG031867/AG/NIA NIH HHS; R01AG031867/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Nerve Tissue Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conformational Preferences of Modified Nucleoside N(4)-Acetylcytidine, ac(4)C Occur at "Wobble" 34th...
Next Document:  Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' f...